We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Zoladex

News List

AstraZeneca Enters Agreement with TerSera Therapeutics for Zoladex in the US and Canada americanpharmaceuticalreview
February 22, 2017
AstraZeneca has entered into an agreement with TerSera Therapeutics LLC (TerSera) for the commercial rights to Zoladex (goserelin acetate implant) in the US and Canada. Zoladex is an injectable luteinising hormone-releasing hormone agonist,
AstraZeneca enters agreement with TerSera Therapeutics for Zoladex in the US and Canada worldpharmanews
February 21, 2017
AstraZeneca today announced that it has entered into an agreement with TerSera Therapeutics LLC (TerSera) for the commercial rights to Zoladex (goserelin acetate implant) in the US and Canada.